$CLYM Income Statement | Understand Stock

$CLYM

$9.57 +$0.76 (8.63%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating expenses:
Acquired in-process research and development, related party
Research and development expense
Research and development, related party
General and administrative
Total operating expenses
Total loss from operations
Other income (expense):
Change in fair value of redeemable convertible preferred stock tranche liability
Other Income, net
Foreign currency gain (loss)
Foreign currency (loss) gain
Interest income, net
Foreign currency loss
Interest income
Total other income (expense)

Net loss
Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
Other comprehensive income (loss):
Unrealized gain on investments, net of tax of $0
Unrealized gain on marketable securities
Comprehensive loss
Net loss per share, diluted
Net loss per share, basic
Weighted-average number of shares used to compute net loss per share, diluted
Weighted-average number of shares used to compute net loss per share, basic

Comments